@article{MAKHILLRJMS202317729325,
    title = {Distribution of HER2/neu Overexpression in Gastric and Esophageal Carcinomas: A Cross-Sectional Study},
    journal = {Research Journal of Medical Sciences},
    volume = {17},
    number = {7},
    pages = {1070-1075},
    year = {2023},
    issn = {1815-9346},
    doi = {10.59218\makrjms.2023.1070.7075},
    url = {https://makhillpublications.co/view-article.php?issn=1815-9346&doi=10.59218\makrjms.2023.1070.7075},
    author = {R.},
    keywords = {HER2/neu overexpression, gastric carcinomas, esophageal carcinomas},
    abstract = {<p style="text-align:justify">Human epidermal growth factor receptor 2 (HER2/neu) overexpression has been identified as an important prognostic and predictive factor in certain types of cancers. While it&#39;s well-characterized in breast cancer, its distribution in gastric and esophageal carcinomas remains less understood. To investigate the distribution of HER2/neu overexpression in patients with gastric and esophageal carcinomas and its potential clinical implications. Methods: In this cross-sectional study, we assessed HER2/neu expression in biopsy samples from patients diagnosed with gastric and esophageal carcinomas. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) techniques were utilized. Clinico-pathological data, including tumor type, grade, stage and other relevant markers, were also collected and analyzed. A total of 470 patients were enrolled in the study. HER2/neu overexpression was noted in 16.2% of gastric carcinomas and 11.9% of esophageal carcinomas. The overexpression of HER2/neu displayed a notable association with higher tumor grades, with the medium and high-grade tumors showing increased overexpression as compared to low-grade tumors. Furthermore, the advanced stage of tumors exhibited a higher prevalence of HER2/neu overexpression compared to the early stages, particularly evident in gastric carcinomas. However, when evaluating other clinico-pathological parameters, such as the presence of hypothetical molecular markers A and B, no statistically significant correlation with HER2/neu overexpression was determined. HER2/neu overexpression is prevalent in a notable proportion of gastric and esophageal carcinomas, with associations to more aggressive tumor features. This insight underscores the importance of HER2/neu evaluation in these cancers and suggests potential therapeutic implications.</p>
}
    }